The VIANEX Group was honored with the Award for “Business Tradition and Progress” at the Athens Chamber of Commerce and Industry (ACCI) Awards, confirming its enduring presence and contribution to the development of the Greek pharmaceutical industry and the national economy. The award ceremony took place on Wednesday, June 3rd at the Athens Concert Hall, in the presence of government representatives, the business community, and institutional bodies.
Read: VIANEX Group participated dynamically in Rebrain Greece in London
VIANEX Group: The value of distinction
This particular distinction holds special significance for the VIANEX Group, as it validates a steady and continuous path of development, extroversion, and contribution, based on a history that now spans over a century of presence in the pharmaceutical sector in Greece. At the same time, it highlights the Group’s steadfast commitment to a culture of responsibility, centered on humanity and the provision of the good of Health.
Dimitris Giannakopoulos: “Commitment to continuity”
During the award acceptance, the Chairman and CEO of VIANEX Group, Mr. Dimitris Giannakopoulos, stated among other things: “An award from ACCI always holds particular weight for us. The late Pavlos Giannakopoulos was an active member of the Chamber and served in various positions of responsibility for eight consecutive years. However, I dare say that today ACCI is experiencing perhaps the best period of its modern course, with substantial contribution to strengthening entrepreneurship and the country’s development prospects.
We receive this award as recognition of a journey that now spans over a century, but also as a commitment to continuity. As the next generation of Management, honoring the legacy of Pavlos Giannakopoulos, we have today almost tripled our sales percentages and continue to invest in development, innovation, and our people, with the goal that VIANEX remains at the top of the Greek pharmaceutical industry and continuously creates value for society and the country.”
Today, the VIANEX Group constitutes the largest productive force in the Greek pharmaceutical industry, operating four state-of-the-art production facilities and maintaining presence in more than 100 countries through an extensive network of international partnerships. The Group’s Management continues consistently on its development path, leveraging its strong legacy and strategically investing in innovation, extroversion, new technologies, and strengthening Greek production, with the goal of shaping the future of Healthcare.
